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ScienceDirectAntigen-specific immunotherapy is considered the holy-grail
for treatment of autoimmune diseases. However, unlike the
unattainable myth of Arthurian legend, effective antigen-
specific immunotherapy is now being realised through clinical
trials in patients. This review describes the various approaches
being taken, how antigens are being designed for therapy and
carriers created for their delivery. A critical assessment is made
concerning the need for such carrier systems.
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Introduction
It is estimated that 1/20 people suffer from one or more
autoimmune diseases [1]. Furthermore, the 4 to 8% per
annum increase in incidence of these diseases is a major
concern (Table 1) [2]. Most autoimmune diseases are
poorly managed by non-specific immunosuppressive
drugs and there is currently no cure for the pathological
mechanisms underlying these conditions.
Antigen-specific immunotherapy has been used for the
control of allergy for over 100 years [3]. The mechanism
by which allergic desensitisation controls allergy is not
clear although it is known that T cells alter their cytokine
secretion [4] and can support the generation of ‘blocking’
antibodies [5].
Antigen-specific immunotherapy is seen as the ‘holy grail’
for effective treatment of autoimmune diseases [6], it
satisfies the need to induce protective immunity targeted
to pathogenic T cells while avoiding non-specific immune
suppression. The aim is to reinstate tolerance towards
self-antigens while leaving the rest of the immune systemwww.sciencedirect.com capable of controlling infections and cancers. This review
will describe recent advances in engineering self-antigens
and creating novel platforms for their delivery to reinstate
tolerance (Figure 1).
Tolerogenic DC for autoimmune diseases
The immune system generally remains dormant when
faced with the myriad of self-antigens exposed throughout
the body while responding rapidly and strongly to foreign
antigens contained within infectious agents or the neoan-
tigens resulting from mutations associated with cancer. In
the case of infectious agents, the immune system is
activated by recognition of pathogen-associated molecular
patterns (PAMPS) from infectious agents. Dendritic cells
(DCs) are the key antigen presenting cells (APCs) for
activation of both CD4 and CD8 T-cells and are especially
adapted to respond to PAMPS. Most importantly, Stein-
man and colleagues provided evidence that these cells are
tolerogenic (see Box 1) in the immature/steady state and
only promote strong immune responses when activated
through ligation of receptors for PAMPS and other
‘danger’ signals [7]. Immature/steady state DC have low
levels of the MHC class II and the costimulatory mole-
cules (CD40, CD80 and CD86) required for effective
activation of T cells. In addition, these immature DC
secrete low levels of cytokines such as IL-12 that drive
differentiation of effector T cells while having higher
levels of anti-inflammatory cytokines such as IL-10. Anti-
gens presented by tolerogenic DC are seen by T cells but
this encounter results in T cell death, anergy or the
adoption of a regulatory (Treg) phenotype.
Various groups have sought means of preventing matura-
tion of DC by treating immature cells with drugs, includ-
ing vitamin D3, steroids and rapamycin [8] or by genetic
manipulation. For example, DC can be treated with anti-
sense oligonucleotides specific for CD40, CD80 and
CD86 to create a tolerogenic population [9]. In a phase
1 study, 10 patients with type 1 diabetes were treated with
DC either unmanipulated or engineered towards an
immunosuppressive state ex vivo. The treatment was well
tolerated although there was no significant change in
relevant biomarkers.
Two studies of the use of tolerogenic DC for treatment of
rheumatoid arthritis (RA) were published recently. Hilk-
ens and Isaacs developed a method for engineering
tolerogenic DC using dexamethasone, vitamin D3 and
monophosphoryl lipid A [10]. The resulting cells display a
tolerogenic phenotype, suppress T cell proliferation andCurrent Opinion in Chemical Engineering 2018, 19:35–42
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Table 1
Increasing incidence and prevalence of immune mediated inflammatory diseases (IMIDs). The net %/year increase in categories of IMIDs
including multiple sclerosis (MS), autoimmune hepatitis (AIH), inflammatory bowel disease (IBD), insulin dependent diabetes mellitus
(IDDM), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). From Lerner et al. (2015). Prevalence of the diseases shown is
from Hayter and Cook (2012)
Organ/system Significance Mean net increase
(%/year)
Countries of combined studies Examples of IMIDs Disease prevalence/105
Neurological <0.0001 3.7  2.5 Finland, Denmark, Norway, Italy,
Spain
MS 58
Myasthenia gravis 5.1
Narcolepsy 30.6
Gastrointestinal <0.0001 6.2  11.5 Denmark, Canada, Sweden, USA,
Finland, Israel, Netherlands, UK,
Czech, Scotland, Spain, Estonia,
New Zealand
AIH type 1 16.9
AIH type 2 3
IBD 55
Celiac disease 750
Pernicious anaemia 151
Endocrine 0.02 6.3  4.2 Brazil, Canada, Israel, Serbia,
Europe, Canada, UK
Addison’s disease 14
Rheumatic 0.02 7.14  1.5 Graves’ disease 629
Hashimoto’s thyroiditis 792
IDDM 480
RA 860
SLE 32secretion of interferon gamma and IL-17. Most impor-
tantly, DC treated in this way remained refractory to
further challenge with pro-inflammatory cytokines in
vitro. Equivalent cells pulsed with collagen type II had
been shown to inhibit collagen-induced arthritis in mice
[11]. On the basis of the success of this approach in mice,
tolerogenic DCs were pulsed with autologous synovial
fluid as a source of autoantigens and introduced into the
inflamed joints of RA patients [12]. The treatment was
well tolerated with evidence of disease stabilisation in
two individuals; however, no clinical or immunomodula-
tory effects were noted.
Thomas and colleagues have developed a similar
approach using suppression of the NF-kB pathway as a
means of generating tolerogenic DC. DCs modified with
the NF-kB inhibitor, Bay11-7082, suppressed arthritis in
an antigen-specific manner in mice [13]. Consequently,
Benham and colleagues tested administration of Bay11-
7082-treated DC pulsed with peptide antigens from
citrullinated protein antigens [14]. These antigens are
found within inflamed joints of RA patients and anti-
citrullinated protein antibodies (ACPA) are generated in
the majority of RA patients [15]. DCs were administered
once intradermally to 18 ACPA +ve patients. The treat-
ment was well tolerated and there was evidence of an
increase in the ratio of Treg/effector cells.
The studies described above demonstrate that it is possi-
ble to alter autoimmune phenomena in vivo by targeting
antigens to tolerogenic DCs. This supports previous
results from experimental models of multiple sclerosis
(EAE), rheumatoid arthritis and type 1 diabetes [16].
Interventions in human disease are promising, well toler-
ated and a valid strategy for therapeutic tolerance in
autoimmune disease.Current Opinion in Chemical Engineering 2018, 19:35–42 Cell-free therapeutic approaches based on
liposomes and red blood cells
These approaches have arisen from the original work of
Miller and colleagues who showed the tolerogenic
effect of splenocytes pulsed with antigen and then
fixed with ethylene carbodiimide (ECDI) [17]. It was
believed that these cells presented antigen but with
disrupted costimulatory capacity following fixation.
Subsequent studies showed, however, that the fixed
APC could be replaced by antigen coupled directly to
beads [18]. This revealed that cells pulsed with antigen
and fixed with ECDI were carrying antigen to tolero-
genic APC. Collective evidence implied that delivery
of autoantigen to tolerogenic DC or the coincidental
delivery of autoantigens with drugs designed to sustain
the immature phenotype of DC in vivo could substitute
for the transfer of tolerogenic DC (see Table 2). Pujol-
Autonell created liposomes containing phosphatidyl-
serine so as to mimic the surface phenotype of apopto-
tic cells, known to promote tolerogenic DC [7], and
loaded them with antigenic peptide [19]. These lipo-
somes reduced clinical symptoms of the mouse model
of MS (EAE) when loaded with a myelin-antigen
peptide and administered before disease induction.
Kontos and colleagues followed a similar logic based
on the clearance of senescent red blood cells [20]. They
engineered antigen constructs to target antigens to
erythrocyte cell surfaces after i.v. injection. This
induced cell proliferation and apoptotic T-cell death
in a cell transfer model of type 1 diabetes. It seems
likely, however, that bystander suppressive mecha-
nisms will be needed for effective immunotherapy of
the many autoimmune diseases that are not limited to
single antigens; this is not provided by such an apopto-
tic mechanism. With this in mind, Capini and collea-
gues created phosphatidycholine liposomes loadedwww.sciencedirect.com
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Figure 1
BLOOD MONOCYTES TOLEROGENIC DC
SYNTHETIC PEPTIDES
ARTIFICIAL APCLIPOSOME NANOPARTICLE
Antigen
Antigen
± Drug
± Drug
(a)
(b) (c)
(d)
Current Opinion in Chemical Engineering
Novel approaches to antigen-specific immunotherapy of autoimmune diseases: (a) Tolerogenic DCs are generated from the patient’s blood-
derived monocytes using various immunosuppressive agents to prevent DC maturation. Tolerogenic DC are pulsed with antigen and injected back
into the patent. (b) Self-antigens are encapsulated or attached to liposomes or PGLA-nanoparticles. Drugs such as NFkB inhibitors may be added
so as to prevent DC maturation in vivo. (c) Nanoparticles may be loaded with complexes derived from patients MHC II protein with self-antigen
peptide pre-loaded. (d) Self-antigen derived T cell epitopes are optimised for solubility and MHC binding and injected directly without carrier or
adjuvant. Details of these approaches and the outcome of their use are given in the text.with antigen and a lipophilic NF-kB inhibitor [21].
These liposomes are taken up by macrophages and
DC in which they suppress NF-kB signalling. Treat-
ment of mice with these liposomes led to an increase in
the ratio of Treg:effector cells and produced a signifi-
cant reduction of clinical disease in a mouse model of
arthritis. These approaches show promise as alterna-
tives to the generation and delivery of antigen-pulsed
tolerogenic DCs.www.sciencedirect.com Cell-free therapeutic approaches base on
nanoparticles
In an analogous approach to the work described by
Capini et al., Kishimoto and colleagues developed an
approach based on nanoparticles loaded with rapamy-
cin. Rapamycin prevents maturation of DC and thereby
holds the APC in a tolerogenic state [22]. Maldonado
and colleagues originally combined protein or peptide
antigens with rapamycin in biodegradable nanoparticlesCurrent Opinion in Chemical Engineering 2018, 19:35–42
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Box 1 Preferred features of tolerogenic dendritic cells
A Ability to process antigens or bind peptides directly via MHC class II at the cell surface
B Reduced levels of class II MHC. Low levels of costimulatory molecules such as CD40, CD80 and CD86. Higher levels of inhibitory
receptor ligands including PD-L1
C High ratio of anti-inflammatory (IL-10) versus pro-inflammatory (IL-12) cytokines
D Ability to induce apoptotic cell death, anergy or the generation of regulatory T cells as a result of antigen presentation
E Migration to lymphoid organs and stability in vivo
F Resistance to DC maturation through ligation of toll-like receptors, CD40, etc.
Table 2
Carriers for antigen-specific immunotherapy of autoimmune diseases. This table gives examples of therapeutic approaches currently
under development for treatment of autoimmune diseases. At this time, efficacy of these approaches has been demonstrated in mouse
models of disease. There are no published reports of their use in human autoimmune diseases
Carrier Antigen-delivery mechanism Immunosuppressive mechanism Disease model tested
PS liposomes Phosphatidylserine
liposomes containing
antigen
Uptake by and maintenance of a
tolerogenic phenotype in DC.
Increase in LAG-3 expression by
T cells
Experimental autoimmune
encephalomyelitis (EAE) in
mouse
Red blood cell (RBC) Antigen modified with RBC
binding peptide or antibody
fragment
T cell proliferation resulting in
apoptosis of antigen-specific T
cells
T cell transfer model of type
1 diabetes in mouse
PC liposomes and NFkB inhibitor Phosphatidylcholine
liposomes containing
antigen and NFkB inhibitor
Uptake by macrophages and
DC. Increase in Foxp3+ Treg
cells and IL-10 secretion
Methylated bovine serum
albumin induced arthritis in
mouse
NP and RAPA PLGA nanoparticles with
antigen and rapamycin
Uptake by macrophages and
DC. Increase in Foxp3+ Treg
cells
EAE in mouse
NP PLGA nanoparticles with
antigen
Negatively charged particles are
taken up by MARCO +ve
monocytes and macrophages
resulting in T cell anergy and
increase in Treg cells
EAE in mouse
Artificial APC MHC-peptide complexes
were linked to dextran-
coated or pegylated iron
oxide nanoparticles
Direct recognition by antigen-
specific T cells resulting in
generation of Tr1-like regulatory
T cells
EAE, collagen induced arthritis
and type I diabetes in the mouse[23]. This led to suppression of the autoimmune response
to self-antigens in mouse models. More recently, Kishi-
moto and colleagues have shown that the approach
depends on rapamycin being encapsulated within poly
(lactic-co-glycolic acid) (PLGA) particles but their evi-
dence suggests that the nanoparticles do not have to
contain antigen [24]. This implies that the key feature
of this approach is delivery of rapamycin to the DC and that
co-administered antigen is taken up by the tolerogenic DC.
However, this interpretation is challenged by the results of
others showing that PLGA nanoparticles can be effective
without inclusion of rapamycin or any other immunosup-
pressive agent [25]. PLGA nanoparticles containing pep-
tide antigens from myelin alone were shown to prevent and
treat EAE in mice by upregulating PD-L1 on APCs and
suppressing secretion of inflammatory cytokines by anti-
gen-specific T cells. Antigen-specific immunotherapy with
these nanoparticles depends on optimal engineering based
on composition, size, charge and route of administration
[26].Current Opinion in Chemical Engineering 2018, 19:35–42 An alternative nanoparticle-based approach has been
developed by Herkel and colleagues. This is based on
the observation that expression of myelin basic protein
(MBP) in liver tissue results in TGF-b dependent gen-
eration of Foxp3+ Treg cells that suppress induction of
EAE in a mouse model [27,28]. Nanoparticles were
designed to target liver sinusoidal endothelial cells
(LSECs) since presentation of antigen by LSECs induces
tolerance both CD4+ and CD8+ cells [29,30]. Nanoparti-
cles were prepared from superparamagnetic iron oxide
nanocrystals encapsulated in an amphiphilic polymer
(poly(maleic anhydride-alt-1-octadecene)) and were
shown to selectively target LSECs [31]. Nanoparticles
coated with peptides from MBP induced Foxp3+ Treg
cells and reversed ongoing disease.
It is clear that nanoparticles can deliver antigen to endog-
enous tolerogenic pathways in the immune system
thereby providing disease control without inclusion of
immunosuppressive drugs. The major challenge is towww.sciencedirect.com
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suppression since this will be essential for control of most
autoimmune diseases.
Design of artificial APCs
A further development of the nanoparticle approach was
described by Santamaria and colleagues [32]. This
creates artificial APC by coating nanoparticles with com-
plexes of MHC class II molecules and antigenic peptides.
These artificial APCs have optimal dimensions and spac-
ing of MHC molecules for T cell receptor ligation but
lack costimulatory molecules [33]. The artificial APCs
directly modify antigen-specific Th1 cells by inducing
Tr1-like cells capable of bystander suppression. Tr1 cells
specific for one antigen mediate IL-10-dependent
bystander suppression of T cell responses to other anti-
gens when they are presented by the same APC [32,34].
The lack of costimulatory molecules on these artificial
APC means that they interact with effector cells, such as
Th1 cells, but do not modify the function of naı¨ve T cells.
As such, unlike other forms of antigen-specific immuno-
therapy that target tolerogenic DC, MHC-Ag bearing
nanoparticles will suppress ongoing autoimmune diseases
[32] but will not serve as preventive treatments since
they do not engage naı¨ve T cells for which at least low
level costimulatory signalling is required.
Design of synthetic peptides for antigen-
specific immunotherapy
The ideal antigen-specific immunotherapy should allow
repeated administration and induce a bystander suppres-
sive mechanism in order to control the immune response
to the range of antigens associated with autoimmune
diseases. Is it necessary to use sophisticated delivery
systems to produce this outcome? Weiner and colleagues
originally provided evidence that autoimmune diseases
could be controlled by oral delivery of autoantigens
through induction of bystander suppression [35]. Whi-
tacre and colleagues subsequently demonstrated, how-
ever, that high, repeated doses of protein were required
for effective oral tolerance in the mouse model of multi-
ple sclerosis. Such levels of protein would be impractical
for use of this approach in humans [36] and would explain
why trials of oral tolerance in human autoimmune dis-
eases did not provide clinical benefit [37].Box 2 Preferred features of tolerogenic synthetic peptides
A Peptides are highly soluble to avoid entrapment and destru
B Peptides target tolerogenic DC
C Peptides mimic naturally processed antigens when bound t
D Peptides bind directly to MHC on tolerogenic DC
E Repeated administration suppresses secretion of inflammat
Treg cells and anti-inflammatory cytokines (IL-10)
F Regulatory mechanism induced by peptide mediates bystan
G Administration of peptides derived from self-antigens is saf
www.sciencedirect.com Further development of autoantigen-directed tolerance
demonstrated that whole autoantigens could be replaced
by synthetic peptides representing the T cell epitopes
involved in disease, and that parenteral injection was
more effective than mucosal administration of antigen
[38]. We have known for many years that administration
of soluble peptide antigens both prevents and treats
autoimmune conditions without the need for complex
carriers [39–41]. Furthermore, we have defined key rules
governing the design of effective therapeutic peptides
(see Box 2).
Soluble peptide injection induces a state of anergy among
antigen-specific T cells [42,43], this coincides with sup-
pression of pro-inflammatory cytokine production and
upregulation of the anti-inflammatory cytokine IL-10
[41,42]. The resulting Tr1-like cells mediate negative
feedback regulation of the inflammatory immune
response [44] and are capable of bystander suppression
[34,45].
The induction of Tr1-like cells with peptides correlates
with changes in gene transcription in CD4+ T cells.
Transcription factors, Maf, AhR and NFIL-3, known to
support IL-10 transcription in Tr1 cells [46], are upregu-
lated in T cells following peptide therapy [38,47]. Tr1-
like cells isolated from treated mice upregulate inhibitory
receptors such as PD-1, CTLA-4, LAG-3, TIM-3 and
TIGIT [38] while human Tr1 cells show variable levels
of expression of LAG-3, CD49b [48] and TIM-3 [49].
Peptides must be optimised for solubility and MHC
binding for effective antigen-specific immunotherapy.
Studies with peptides from band 3 protein have shown
that administration of insoluble peptide exacerbates hae-
molytic anaemia in the NZB mouse whereas soluble
peptide prevents disease [50]. Solubility of peptides is
improved by replacing hydrophobic with hydrophilic
amino acids or adding charged amino acids to the N-
termini or C-termini. Most importantly, peptides must be
designed to bind MHC class II molecules in the correct
conformation to induce effective tolerance. The proces-
sing of protein antigens by APC places constraints on both
the range of peptides generated from a protein and the
conformation in which they bind to MHC. As a result, thection at site of injection
o MHC II
ory cytokines by antigen-specific T cells while concomitantly inducing
der suppression
e and well tolerated allowing repeated administration to patients
Current Opinion in Chemical Engineering 2018, 19:35–42
40 Biological engineering: Immunoengineeringinteraction of free peptides with MHC II can generate
complexes that are distinct from those generated follow-
ing antigen processing [51]. This influences which T cell
epitopes induce tolerance. For example, a known peptide
epitope from MBP was shown to bind to MHC in a
dominant cryptic conformation when given in soluble
form and failed to induce tolerance among self-antigen
reactive T cells [52]. There are two important implica-
tions of this study; first, it shows that peptide epitopes
generated by antigen processing are not guaranteed to
induce tolerance; second, the results imply that tolerance
induction with soluble peptides involves binding to MHC
II without antigen processing. As a result, tolerogenic
epitopes should be designed as antigen processing inde-
pendent epitopes or apitopes so as to ensure that they
bind MHC II in the correct conformation.
Santambrogio and colleagues have shown that immature
DCs differ from other APC subsets, including B cells,
monocytes and mature DC, by having ‘empty’ MHC II at
the cell surface [53,54]. This explains our recent results
showing that tolerogenic peptides/apitopes selectively
bind MHC on these steady-state/immature DC rather
than B cells or monocytes when injected in soluble form
in vivo (Shepard and Wraith, unpublished data). Peptides
designed to mimic naturally processed epitopes without
antigen processing selectively bind to tolerogenic DC and
this explains why they induce tolerance. Repeated injec-
tion of these peptides in a dose escalation protocol pro-
motes the generation of Tr1-like cells capable of pre-
venting and controlling autoimmune diseases [38].
Further work has indicated that the consequences of
peptide treatment depend on ‘strength of signal’ as
governed by dose and the MHC binding affinity of a
given T cell epitope. While low to moderate affinity
peptides induce T cell anergy, higher affinity analogues
promote IL-10 secretion by the anergic T cells [55]. It is
important to optimise peptide-MHC binding affinity
given the critical role of IL-10 in bystander suppression
and the anti-inflammatory properties of this cytokine.
Clinical experience with tolerogenic peptides
Antigenic peptides have been used to treat various hyper-
sensitivity conditions including allergies [56,57], food
hypersensitivity [58] and autoimmune diseases includ-
ing type 1 diabetes [59,60] and multiple sclerosis
[61,62,63]. These early phase clinical trials of immuno-
therapy with synthetic peptides provide supporting evi-
dence that the mechanisms delineated in murine models
translate well to man. Two overriding conclusions can be
drawn: first, effective control of disease requires repeated
exposure to the peptide antigens and second, that anti-
gen-specific immunotherapy with synthetic peptides has
been shown to be safe and well tolerated thereby allowing
the repeated administration of peptide that will be
required for effective control of autoimmune diseases.Current Opinion in Chemical Engineering 2018, 19:35–42 Conclusions
This review has discussed various approaches used cur-
rently to induce antigen-specific immunotherapy of auto-
immune diseases. This reveals how important it is to
target tolerogenic DC with either free peptide or antigen
associated with a carrier and/or immunosuppressive drug.
The various approaches engage different mechanisms of
tolerance (T cell deletion, anergy, induction of Foxp3+
Treg or Tr1-like Treg cells): it is critically important to
test these for efficacy in different autoimmune patholo-
gies. Moreover, questions remain about the long-term
safety of carrier materials when administered to patients
repeatedly. At this time, only the soluble peptide
approach has undergone extensive clinical testing and
this, the most straightforward of the approaches reviewed,
has proven safe and well tolerated.
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